Huttunen et al. showed that attacking several SLCs to alter the nutrient environment of cancer cells could serve as adjuvant therapy for other chemotherapeutic drugs, providing an alternative to ABC transporter inhibitors[157]. This evidence concerns the gene ABCG2 and cancer.